Viking Therapeutics, Inc. - 10-Q Filing
Viking Therapeutics reports third quarter 2026 financial results including research and development expense trends and convertible senior note details.
Tickers: $VKTX
Read the full article at SEC EDGAR
Part of the story BriaCell Therapeutics Corp. - 10-K Filing (3 articles)